Serum CA125 Concentration has Inverse Correlation with Metabolic Syndrome

被引:12
作者
Joo, Nam-Seok [2 ]
Kim, Kyu-Nam [2 ]
Kim, Kyung Soo [1 ]
机构
[1] Catholic Univ Korea, Dept Family Med, Seoul 137040, South Korea
[2] Ajou Univ, Sch Med, Dept Family Practice & Community Hlth, Suwon 441749, South Korea
关键词
CA-125; Metabolic Syndrome; Korean; BODY-MASS INDEX; OVARIAN-CANCER; EPITHELIAL OVARIAN; INSULIN-RESISTANCE; CA; 125; RISK; MORTALITY; OBESITY; ASSOCIATION; PROSTATE;
D O I
10.3346/jkms.2011.26.10.1328
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Serum carbohydrate antigen 125 (CA-125) is a marker of ovarian cancer and obesity that is related with an increased risk of ovarian cancer. Obesity is a key factor of metabolic syndrome. We evaluated the relationship between CA-125 concentration and metabolic syndrome. The data from subjects who had any cancer and chronic infection were excluded. The data of 12,196 healthy Korean women were analyzed. After CA-125 concentration was divided by quartiles, the prevalence of metabolic syndrome and its components were compared. The lowest quartile of CA-125 compared with the highest quartile showed elevated values of most of metabolic parameters. In addition, as the quartile of CA-125 increased, metabolic derangement decreased. Increased numbers of metabolic syndrome components showed an inverse association with CA-125 levels (P < 0.001). The odds ratio (OR) for the lowest CA-125 quartile vs the highest CA-125 quartile significantly increased in the presence of metabolic syndrome (OR = 1.202, 95% Confidence Interval [CI] 1.013-1.423), elevated triglyceride (OR = 1.381, 95% CI 1.167-1.633), and low high-density lipoprotein cholesterol (OR = 1.168, 95% CI 1.039-1.312). The presence of metabolic syndrome, elevated triglyceride, or low high-density lipoprotein cholesterol negatively correlates with CA-125 concentration.
引用
收藏
页码:1328 / 1332
页数:5
相关论文
共 23 条
[1]   The metabolic syndrome - a new worldwide definition [J].
Alberti, KGMM ;
Zimmet, P ;
Shaw, J .
LANCET, 2005, 366 (9491) :1059-1062
[2]   CA 125: The past and the future [J].
Bast, RC ;
Xu, FJ ;
Yu, YH ;
Barnhill, S ;
Zhang, Z ;
Mills, GB .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1998, 13 (04) :179-187
[3]   Endometrial cancer incidence trends in Europe: Underlying determinants and prospects for prevention [J].
Bray, F ;
Silva, ID ;
Moller, H ;
Weiderpass, E .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (05) :1132-1142
[4]  
Colangelo LA, 2002, CANCER EPIDEM BIOMAR, V11, P385
[5]   Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk [J].
Furberg, AS ;
Veierod, MB ;
Wilsgaard, T ;
Bernstein, L ;
Thune, I .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (15) :1152-1160
[6]   The epidemiology of CA-125 in women without evidence of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial [J].
Johnson, Christine C. ;
Kessel, Bruce ;
Riley, Thomas L. ;
Ragard, Lawrence R. ;
Williams, Craig R. ;
Xu, Jian-Lun ;
Buys, Saundra S. .
GYNECOLOGIC ONCOLOGY, 2008, 110 (03) :383-389
[7]   Prevalence of the metabolic syndrome and its association with cardiovascular diseases in Korea [J].
Kim, MH ;
Kim, MK ;
Choi, BY ;
Shin, Y .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2004, 19 (02) :195-201
[8]   Metabolic syndrome and development of diabetes mellitus: Application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study [J].
Laaksonen, DE ;
Lakka, HM ;
Niskanen, LK ;
Kaplan, GA ;
Salonen, JT ;
Lakka, TA .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2002, 156 (11) :1070-1077
[9]   Epidemiological and Genetic Factors Associated With Ovarian Cancer [J].
McLemore, Monica R. ;
Miaskowski, Christine ;
Aouizerat, Bradley E. ;
Chen, Lee-may ;
Dodd, Marylin J. .
CANCER NURSING, 2009, 32 (04) :281-288
[10]  
Michaud DS, 2002, J NATL CANCER I, V94, P1293, DOI 10.1093/jnci/94.17.1293